Silence Therapeutics plc

Regulatory Filings • Feb 15, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0422F

Silence Therapeutics PLC

15 February 2018

Additional listing

15 February 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has issued and allotted 30,000 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 21 February 2018. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of shares in issue, following admission, will be 70,021,624. The Company holds no shares in Treasury. 

Enquiries:

Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
Media Enquiries: Optimum Strategic Communications  Mary Clark/ Eva Haas/ Hollie Vile [email protected]	Tel: +44 (0) 20 3714 1788

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSGGUCGPUPRGCA